Akero Therapeutics

Youtube Subscribe

Open: 45.62 Close: 44.34 Change: -1.28

You're running out of time to find out about Akero Therapeutics Stock using an AI.

How much time have you spent trying to decide whether investing in Akero Therapeutics? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Akero Therapeutics are: …

Concept Map

Semantic Network

Stock Summary

Akero Therapeutics, Inc. engages in the development of transformational treatments for patients with serious metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc..

Today's Summary

Akero Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing transformational treatments for patients with serious metabolic diseases marked by high unmet need. Arizona State Retirement System bought a new stake in shares of Akero.

Today's News

Wall Street Analysts Think 29.22% Zacks How Much Upside is Left in Akero Therapeutics, Inc. (AKRO)? Wall Street analysts think 29. 22% How Much upside is left in akero therapeutics, inc. (akro) Akero Therapeutics has 33 employees as of Dec 21. The primary business model is: Life Sciences > ********* ** **** ** > ****** Arizona State Retirement System bought a new stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng sold 25,000 shares of the firms stock on Monday. Akero Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing transformational treatments for patients with serious metabolic diseases marked by high unmet need. With no approved treatments for the disease yet, several drugmakers including Novo Nordisk, Madrigal Pharmaceuticals and Akero. Akero Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of Buy A buy rating indicates that analysts believe AKRO will outperform the market and that investors should add to their positions.

Stock Profile

"Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California."

Keywords

The game is changing. There is a new strategy to evaluate Akero Therapeutics fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Akero Therapeutics are: Akero, Therapeutics, analyst, Wall, Street, buy, rating, and the most common words in the summary are: therapeutic, pharmaceutical, akero, pharma, stock, inc, bioscience, . One of the sentences in the summary was: Akero Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing transformational treatments for patients with serious metabolic diseases marked by high unmet need. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #therapeutic #pharmaceutical #akero #pharma #stock #inc #bioscience.

Read more →

Youtube Subscribe

---